EGFR and non-small cell lung carcinoma: Togashi Y et al. found that among patients with pulmonary metastases, 11 of 22 patients (50%) harboring EGFR mutations had miliary pulmonary metastasis compared with the presence of miliary pulmonary metastasis in 4 of 33 (12.1%) patients with wild-type EGFR (p value = 0.0043), and Wu et al. reported that advanced NSCLC patients with MIPC had a higher EGFR mutation rate than patients without MIPC (70% versus 56%, p value = 0.036)4,6.